Baird downgraded Theravance Biopharma (NASDAQ: TBPH) from Neutral to Underperform with a price target of $21.00 saying the valuation can't ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE